The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial

Journal:

Nature Medicine

Published:

2026-03-30

DOI:

10.1038/s41591-026-04313-w

Affiliations:

8

Authors:

12

Go to article

Institutions	Authors	Share
Mass General Brigham, United States of America (USA)	3.000000	0.25
Novartis, Switzerland	2.000000	0.17
Novartis Pharmaceuticals Corporation, United States of America (USA)	2.000000	0.17
University of Glasgow, United Kingdom (UK)	1.000000	0.08
Duke University, United States of America (USA)	1.000000	0.08
Duke-NUS Medical School, Singapore	1.000000	0.08
University of Groningen (RUG), Netherlands	1.000000	0.08
Novartis Pharmaceuticals UK Ltd, United Kingdom (UK)	1.000000	0.08

Interested in Cardiovascular Medicine and Haematology?